Collegium Pharmaceutical, Inc. Payments to Acquire Marketable Securities
Collegium Pharmaceutical, Inc. (COLL) reported Payments to Acquire Marketable Securities of $20.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $1.99M, a 88.01% decline year-over-year.
- Collegium Pharmaceutical, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $18.11M, a 30.05% decline year-over-year.
- Collegium Pharmaceutical, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $39.22M, a 44.37% increase year-over-year.
- Collegium Pharmaceutical, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $45.24M, a 326.84% increase year-over-year.
- Collegium Pharmaceutical, Inc. payments to acquire marketable securities for fiscal 2025 was $126.97M, a 14.21% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. payments to acquire marketable securities for fiscal 2024 was $111.17M, a 20.38% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. payments to acquire marketable securities for fiscal 2023 was $92.35M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $20.10M 10-Q · filed 2026-08-06 | $59.32M derived: sum of 3 quarters · filed 2026-08-06 | $104.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $18.11M 10-Q · filed 2026-05-07 | $57.33M derived: sum of 2 quarters · filed 2026-05-07 | $102.58M derived: sum of 3 quarters · filed 2026-05-07 | $119.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $39.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $84.47M derived: sum of 2 quarters · filed 2026-02-26 | $101.08M derived: sum of 3 quarters · filed 2026-08-06 | $126.97M 10-K · filed 2026-02-26 |
| 2025-09-30 | $45.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $61.86M derived: sum of 2 quarters · filed 2026-08-06 | $87.75M 10-Q · filed 2025-11-06 | $114.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $16.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $42.50M 10-Q · filed 2026-08-06 | $69.67M derived: sum of 3 quarters · filed 2026-08-06 | $80.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $25.89M 10-Q · filed 2026-05-07 | $53.06M derived: sum of 2 quarters · filed 2026-05-07 | $63.66M derived: sum of 3 quarters · filed 2026-05-07 | $97.95M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $27.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $37.77M derived: sum of 2 quarters · filed 2026-02-26 | $72.06M derived: sum of 3 quarters · filed 2026-02-26 | $111.17M 10-K · filed 2026-02-26 |
| 2024-09-30 | $10.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $44.89M derived: sum of 2 quarters · filed 2025-11-06 | $84.00M 10-Q · filed 2025-11-06 | $124.94M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $34.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $73.40M 10-Q · filed 2025-08-07 | $114.34M derived: sum of 3 quarters · filed 2026-02-26 | $124.09M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $39.11M 10-Q · filed 2025-05-08 | $80.04M derived: sum of 2 quarters · filed 2026-02-26 | $89.80M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $40.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $50.69M derived: sum of 2 quarters · filed 2026-02-26 | $92.35M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $9.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $51.42M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $41.66M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |